Indiana University Gastrointestinal Motility Diagnosis Registry (NCT04506593)
Gastrointestinal Motility Diagnosis Registry
🩺 Plain-English Summary (8th-Grade Level)
Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders
Who can join: Review the eligibility criteria below.
Location: Indiana University Health University Hospital — Indianapolis, Indiana
🧪 Interventions in This Study
- no intervention (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Indiana University Health University Hospital — Indianapolis, Indiana
📞 Contact the Study Coordinator
Phone: (317) 278-0621
Email: larcohen@iu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Esophagitis
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis — Phoenix, Arizona
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children — Chicago, Illinois
- A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- Dupilumab for Eosinophilic Esophagitis With Severe Strictures — Chapel Hill, North Carolina
- Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks — Little Rock, Arkansas
Explore by condition: All Eosinophilic Esophagitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.